Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

QX Teng, ZN Lei, JQ Wang, Y Yang, ZX Wu… - Drug Resistance …, 2024 - Elsevier
Aims The overexpression of ABC transporters on cancer cell membranes is one of the most
common causes of multidrug resistance (MDR). This study investigates the impact of ABCC1 …

[PDF][PDF] PARP inhibitors in advanced ovarian cancer: a review of long-term efficacy and survival rates

B Scott - ONCOLOGY, 2021 - emjreviews.com
Ovarian cancer is the seventh most common cancer in women and the most lethal
gynaecological malignancy. The latest breakthrough in the management of newly …

[HTML][HTML] Identification of solute-carrier family 27A molecules (SCL27As) as a potential biomarker of ovarian cancer based on bioinformatics and experiments

H Chen, T Han, Y Zhao, L Feng - Annals of translational medicine, 2021 - ncbi.nlm.nih.gov
Background Ovarian cancer is one of the 3 major gynecological malignancies with high
mortality, poor prognosis, and lack of specific diagnostic and prognostic markers. Solute …

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on …

L Fan, Y Zhang, P Maguire, D Muston… - Journal of market …, 2022 - Taylor & Francis
Background The economic impact of adverse events (AEs) for poly (ADP-ribose)
polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated …

OVEREXPRESSION OF ABCC1 AND ABCG2 CONFERS RESISTANCE TO BMN-673, A POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS

Q Teng - 2023 - scholar.stjohns.edu
Cancer remains a growing public health challenge worldwide. Although the development of
chemotherapies has effectively reduced the cancer death rate and improved patients' …

[PDF][PDF] 11 [Suppl 1]: 2-12. DOI/10.33590/emjoncol/10300067

B Scott - 2023 - emjreviews.com
Ovarian cancer is the seventh most commonly diagnosed cancer among females and the
most lethal gynaecologic malignancy globally because of its vague presentation, insidious …

[PDF][PDF] Pharmaceutical Sciences

DRDG JOSHI, P Verma, G Jain, S Mungre… - academia.edu
Ovarian cancer being asymptomatic is leading to late diagnosis resulting in increased death
rate worldwide. The development of platinum resistant ovarian cancer, research has paved …

[引用][C] The emerging role of homologous recombination deficiency testing and the progress of PARP inhibitors in advanced ovarian cancer: interviews with three key …

R Ganapathi - EMJ Oncol, 2022